SPERO THERAPEUTICS INC (SPRO)       1.82  -0.03 (-1.62%)

1.82  -0.03 (-1.62%)

US84833T1034 - Common Stock - After market: 1.84 +0.02 (+1.1%)

News Image
a month ago - Spero Therapeutics, Inc.

Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Dec. 22, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company,...

News Image
2 months ago - Spero Therapeutics, Inc.

Spero Therapeutics to Present at the 5th Annual Evercore ISI HealthCONx Conference

CAMBRIDGE, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical...

News Image
3 months ago - Spero Therapeutics, Inc.

Spero Therapeutics Announces Third Quarter 2022 Operating Results and Provides Business Update

Entered into and closed exclusive license agreement with GSK for tebipenem HBr, pursuant to which Spero receives $66 million upfront, and a $9 million...

News Image
3 months ago - Spero Therapeutics, Inc.

Spero Therapeutics Announces Closing of Exclusive License Agreement with GSK for Tebipenem HBr

Pursuant to the agreement, Spero will be receiving a $66 million upfront payment, received a $9 million direct equity investment in shares of Spero common...

News Image
3 months ago - Spero Therapeutics, Inc.

Spero Therapeutics to Provide Business Update and Report Third Quarter 2022 Financial Results on Monday, November 14, 2022

CAMBRIDGE, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company,...

News Image
3 months ago - Spero Therapeutics, Inc.

Spero Therapeutics to Present Data at IDWeek 2022

CAMBRIDGE, Mass., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company,...

News Image
4 months ago - Spero Therapeutics, Inc.

Spero Therapeutics to Host Virtual R&D Event on Non-Tuberculous Mycobacterial Pulmonary Disease and the SPR720 Program

Event is taking place on Thursday, October 6th at 11:30 a.m. ET Event will feature a presentation by key opinion leader, Kevin L. Winthrop, MD, MPH...

News Image
4 months ago - InvestorPlace

Spero Therapeutics (SPRO) Soars 137% on Exclusive License Agreement

Spero Therapeutics (SPRO) stock is rocketing higher on Thursday after the company signed a licensing agreement with GSK (GSK).

News Image
4 months ago - InvestorPlace

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

It's time for an overview of the biggest pre-market stock movers for Thursday and all the news behind this morning's movement.

News Image
4 months ago - Spero Therapeutics, Inc.

GSK and Spero Therapeutics Announce Exclusive License Agreement for Late-Stage Antibiotic Asset, Tebipenem HBr

The exclusive license allows GSK to commercialize tebipenem HBr in all territories, except Japan and certain other Asian countries Spero Therapeutics...

News Image
5 months ago - Spero Therapeutics, Inc.

Spero Therapeutics Announces Appointment of Kamal Hamed, MD, MPH, MBA, as Chief Medical Officer

Dr. Hamed has over 20 years of anti-infective experience and has spearheaded the global development and approval of multiple anti-infective products...

News Image
5 months ago - InvestorPlace

Can Justin Herbert Help SOFI Stock Score a Touchdown?

SoFi Technologies (SOFI) stock is on the move Wednesday as investors react to a multiyear contract with NFL player Justin Herbert.